Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

Celebrating Women's Leadership in Life Sciences on International Women's Day + Johnson & Johnson's Cell Therapy for Multiple Myeloma Gets FDA Approval

Celebrating Women's Leadership in Life Sciences on International Women's Day + Johnson & Johnson's Cell Therapy for Multiple Myeloma Gets FDA Approval

FromXtalks Life Science Podcast


Celebrating Women's Leadership in Life Sciences on International Women's Day + Johnson & Johnson's Cell Therapy for Multiple Myeloma Gets FDA Approval

FromXtalks Life Science Podcast

ratings:
Length:
33 minutes
Released:
Mar 9, 2022
Format:
Podcast episode

Description

In this episode, Ayesha spoke about some of the top women leaders in life science industries in celebration of International Women’s Day. While women remain underrepresented in STEM and life science industries, there are more women in leadership positions at pharmaceutical, biotechnology and medical device companies than ever before. Studies also show that women’s leadership training programs provide effective training for women seeking executive-level positions. The editorial team also shared some of their experiences and insights as women in the life sciences. The editorial team also learned about the FDA approval of a new CAR T cell therapy developed by Johnson & Johnson and Legend Biotech for the treatment of relapsed or refractory multiple myeloma. The drug, called Carvykti, is administered as a single infusion and indicated for patients who have not responded to previous treatments. The cell therapy has a list price of almost half a million dollars due to the high development costs of cell therapies, but makers say the clinical benefit they offer is worth the price. Most insurers and Medicare will cover the cost of Carvykti.Read the full articles here: Looking at Women’s Leadership in Life Science Industries on International Women’s DayJohnson & Johnson’s Carvykti Becomes Second FDA Approved Cell Therapy for Multiple MyelomaFor more life science and medical device content, visit the Xtalks Vitals homepage.Follow Us on Social MediaTwitter: @Xtalks Instagram: @Xtalks Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured
Released:
Mar 9, 2022
Format:
Podcast episode

Titles in the series (100)

This Life Science focused podcast brings together Xtalks editorial staff to share insights into the latest B2B industry news. Xtalks connects professionals in the life science, medical device, and food industries with useful content like webinars, job opening, articles and virtual meetings.